

☒

+

(Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.)

2

<b>Application Number</b>	10/509919
<b>Filing Date</b>	10-04-2004
<b>First Named Inventor</b>	BADORC
<b>Group Art Unit</b>	1625
<b>Examiner Name</b>	RAHMANI, Niloofer
<b>Attorney Docket Number</b>	SSL0082 - US - PCT

[illegible][illegible]

02/21/2008

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/509919
				Filing Date	10-04-2004
				First Named Inventor	BADORC
				Group Art Unit	1625
				Examiner Name	RAHMANI, Niloofar
Sheet	2	of	2	Attorney Docket Number	SSL0082 - US - PCT

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ROSSEELS, et al., Study in the Indolizines Series. V. Effect of Indolizine Substitution I Position 1 in the Butoprozine Series, European J. of Med. Chemistry; 1983; 18(4); pp.339-346.	
		Compounds for Screening, SPECS and bioSPECS XP002224380, Database Chemcats chemical abstracts service, Columbus, Ohio; July 1, 2001	

Examiner Signature	/Niloofar Rahmani/	Date Considered	02/21/2008
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/